204 results
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
Non-vested Warrants | Warrants | Weighted- Average Exercise Price | ||||||
Non-vested at December 31, 2023 | — | $ | — | |||||
Granted | 55,000 | $ | 7.50 | |||||
Vested | (55,000) | $ | 7.50 | |||||
Forfeited | — | $ | — | |||||
Non-vested at March 31, 2024 | — | $ | — |
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
For the Three Months Ended March 31, 2024 | For the Three Months Ended March 31, 2023 | $ Change | % Change | |||||||||||||
Net cash used in operating activities | $ | (1,991,893) | $ | (173,369) | $ | (1,818,524) | (1,049 | )% | ||||||||
Net cash provided by financing activities | 5,665,731 | 166,903 | 5,498,828 | 3,295 | % | |||||||||||
Net increase (decrease) in cash | $ | 3,673,838 | $ | (6,466) | $ | 3,680,304 | (56,918 | )% |
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
For the Three Months Ended | For the Three Months Ended | |||||||
March 31, 2024 | March 31, 2023 | |||||||
OPERATING EXPENSES | ||||||||
General and administrative expenses | $ | 787,561 | $ | 477,630 | ||||
Research and development | 466,606 | 186,117 | ||||||
Professional fees | 679,815 | 250,836 | ||||||
Total operating expenses | 1,933,982 | 914,583 | ||||||
NET LOSS FROM OPERATIONS | (1,933,982) | (914,583) | ||||||
OTHER (EXPENSE) INCOME | ||||||||
Interest expense | (628,348) | (51,978) | ||||||
Total other (expense) income | (628,348) | (51,978) | ||||||
Net loss before provision for income taxes | (2,562,330) | (966,561) | ||||||
Provision for income taxes | — | — | ||||||
NET LOSS | $ | (2,562,330) | $ | (966,561) | ||||
Net loss per common share - basic and diluted | $ | (0.55) | $ | (0.87) | ||||
Weighted average number of common shares outstanding during the year - basic and diluted | 4,690,989 | 1,111,112 |
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
For the Three Months Ended | For the Three Months Ended | |||||||
March 31, 2024 | March 31, 2023 | |||||||
Consultant | $ | 30,033 | $ | 16,400 | ||||
Lab Gas | — | — | ||||||
Lab Cell Storage | 24,127 | 10,100 | ||||||
Chemistry Manufacturing and Controls (“CMC”) | 303,397 | — | ||||||
IP Services | 109,049 | 159,617 | ||||||
Total | $ | 466,606 | $ | 186,117 |
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
Exercise price | $ | 22.68 | ||
Expected dividend yield | 0 | % | ||
Risk free interest rate | 3.61-3.93 | % | ||
Expected life in years | 10 | |||
Expected volatility | 157-158 | % |
10-Q
k10 nu5wnu
15 May 24
Quarterly report
4:06pm
10-Q
ydx75h
15 May 24
Quarterly report
4:06pm
10-Q
gn1o9o2gfei7dhb
15 May 24
Quarterly report
4:06pm
10-Q
uussgnc
15 May 24
Quarterly report
4:06pm
10-Q
fxikj9w8vbq
15 May 24
Quarterly report
4:06pm
10-Q
em5 pathwxhwi
15 May 24
Quarterly report
4:06pm
10-Q
p0oex4
15 May 24
Quarterly report
4:06pm
10-Q
irw 4zed7cc4
15 May 24
Quarterly report
4:06pm
10-Q
25wd7
15 May 24
Quarterly report
4:06pm
10-Q
v7tc86h0ovd9s
15 May 24
Quarterly report
4:06pm
10-K
9iiv2usi8
16 Apr 24
Annual report
4:48pm
10-K
ojv6zaquhrz 0y63mxv
16 Apr 24
Annual report
4:48pm
10-K
tcrpcdhsp0 dfr127r
16 Apr 24
Annual report
4:48pm
10-K
us4 tjblo
16 Apr 24
Annual report
4:48pm
10-K
8sespz34 pjyv
16 Apr 24
Annual report
4:48pm